BSECompany Update4d ago · 16 Oct 2026, 02:55 pm
As per the file enclosed.
Venus Remedies Ltd · 526953
✦ AI Summary▲ PositiveExpansion
Venus Remedies Ltd has secured five marketing authorisations across four key international markets, including Kazakhstan, Peru, Kuwait, and Argentina, expanding its international presence and access to its pharmaceutical portfolio.
Analysis Scores
Earnings Impact2/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact6/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Venus Remedies Ltd - 526953 - Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets
Attachments (1)
📄pdf
Download →
82d143e3-bfc3-4f09-af44-e9cb60379126.pdf
View document text
VENUS
6nioy grinoualions
VRL/SEC/EXCHANGE 16,10.2026
Sub. : Venus Remedies Secures Five Marketing Authorisations Across Four Key International
Markets.
Dear Sir/ Madam,
This is to inform you that Venus Remedies Limited has secured five marketing authorisations across
Kazakhstan, Peru, Kuwait and Argentina, strengthening its international presence and expanding
access to its pharmaceutical portfolio across key global markets.
The approval§ cover Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate
in Kuwait, and Meropenem in Argentina. The authorisations span markets across the CIS region,
Latin America and the Middle East.
"These marketing authorisations mark another step in strengthening our international presence and
expanding our product reach across diverse markets. We remain focused on building a strong global
portfolio and making quality pharmaceutical solutions accessible to more patients worldwide," said
Saransh Chaudhary, Executive Director, Venus Remedies Ltd, and CEO, Venus Medicine Research
Centre OwRC),
The company has a continued focus on expanding its portfolio for exports across geographies and
building opportunities for sustainable international growth.
A leader in critical-care injectables, Venus Remedies has already established an international
footprint in over 100 countries. "Our international growth strategy is centred on expanding our reach
in high-potential markets while strengthening our product portfolio. We are committed to pursuing
new opportunities through regulatory excellence, differentiated offerings and a sustained focus on
global market expansion," said Aditi K. Chaudhary, President, International Business, Venus
Remedies Ltd.
Thanking you.
Yours faithfully,
for VENUS REMEDIES LllvllTED
Neha
(Company Secretary)
M. No. F8374
VENUS REMEDIES LIMITED
C®rp®mt. omc. : Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.)
::,-.52J#|u7S!F2g3%g;#;::-6,9ETFcexT+I;|T|¥2'-23:!!:6'ndia
134113, India
Regd. Ofnce : t'rit.n :
Hill Top lndustnal Estate, Jharmajri EPIP, Pha8€-I, (Extn.),
SCO 857, Cabin No.10, 2nd Floor, NAG, Manimajra,
Bhatoli Kalan, Baddi (H.P.) 173205, India
Chandigarh (U.T.) 160101, India
Tcl. : +91-1792-242100. 242101
Website : www.venusremedies.com
www.vmrcindia.com Uult-V : ©#F#q
email : info©renusremedies.com VENUS PHARMA GmbH wh th gr
AM Bahnhof I-3, D-59368,
CIN No. ; L2`lco2CH1989PLC`009705 Weme, Germany Dun cusTON§